Southeast BIO (SEBIO) Recognizes Argos Therapeutics, Inc. With the "2012 Southeast BIO Deal of the Year: Venture Capital Transaction" Award  
11/2/2012 7:16:09 AM

DURHAM, N.C., Nov. 2, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, was presented with the "2012 SEBIO Deal of the Year: Venture Capital Transaction" award during a ceremony held at the conclusion of Southeast BIO's (SEBIO) 14th Annual Investor Forum on November 1, 2012 in Palm Beach, FL. B. Jefferson (Jeff) Clark, a member of Argos Therapeutics' Board of Directors, accepted the award on the behalf of company.